Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Every row

Showing 8 of 382 rows for Microglia / neuroinflammation target (preclinical). One row per study per exposure: a study that tested two different things appears twice, once for each.

Scroll the table sideways to see every column.

Research and outcomes, 8 rows. Every row links to its source.
Exposure Question Direction Outcome measured Design People Effect size, as the source reported it Source
Microglia / neuroinflammation target (preclinical) Medicines Treatment Benefit
why

Direction is for peripheral cancer in AD mice: tumour-secreted cystatin-C bound amyloid oligomers and activated microglial TREM2, enabling degradation of existing plaques and rescuing cognition; the effect was abolished by microglial deletion or mutation of TREM2 or cystatin-C. Mouse work with no human outcome.

Amyloid plaque load and cognition in AD mice bearing peripheral tumours, and dependence on microglial TREM2 and cystatin-C None not stated not established — pubmed abstract reports no numeric effect size. Cell 2026
✓ Peer-reviewed PMID 41576952
Microglia / neuroinflammation target (preclinical) Medicines Treatment Benefit
why

Direction is for lowering PU.1 in microglia, which reduced the severity of amyloid pathology in mice; microglia-specific CD28 deficiency did the opposite and increased plaque load. Mouse work with no human outcome.

Severity of amyloid pathology in mouse models None not stated not established — pubmed abstract reports no numeric effect size. Nature 2025
✓ Peer-reviewed PMID 41193812
Microglia / neuroinflammation target (preclinical) Medicines Treatment No direction reported
why

A descriptive transcriptional atlas: it maps expression changes, isoform usage, co-expression modules and disease subtypes in microglia from post-mortem brains and estimates no effect of an exposure.

Microglial gene-expression changes associated with dementia severity and neuropathological lesions (ex vivo human microglia) None 189 not established — pubmed abstract reports no numeric effect size. Nature Neuroscience 2025
✓ Peer-reviewed PMID 40760184
Microglia / neuroinflammation target (preclinical) Medicines Treatment Benefit
why

Direction is for deleting TIM-3 in microglia: it increased phagocytic activity, shifted microglia to the disease-associated state, reduced amyloid pathology and improved cognitive impairment in 5xFAD mice. Mouse work with no human outcome.

Microglial phagocytosis, amyloid pathology and cognition in 5xFAD mice after microglia-targeted deletion of TIM-3 (Havcr2) None not stated not established — pubmed abstract reports no numeric effect size. Nature 2025
✓ Peer-reviewed PMID 40205047
Microglia / neuroinflammation target (preclinical) Medicines Treatment Benefit
why

Direction is for blocking the ZBP1-RIPK1 axis: genetic deletion of Zbp1 or inhibition of RIPK1 attenuated neuroinflammation, amyloid pathology and behavioural deficits in AD mice, after showing that amyloid-induced oxidised mitochondrial DNA forms Z-DNA sensed by ZBP1 in microglia. Mouse work with no human outcome.

Neuroinflammation, amyloid pathology and behavioural deficits in an AD mouse model after Zbp1 deletion or RIPK1 inhibition None not stated not established — pubmed abstract reports no numeric effect size. Immunity 2025
✓ Peer-reviewed PMID 40902587
Microglia / neuroinflammation target (preclinical) Medicines Treatment Benefit
why

Direction is for removing the granzyme K-producing CD103-negative CD8+ T cells: their ablation ameliorated cognitive decline and reduced neuropathology in 3xTg-AD mice, and granzyme K caused neuronal dysfunction and tau hyperphosphorylation via PAR-1. Mouse and cell work with no human outcome.

Cognitive decline and neuropathology in 3xTg-AD mice after ablation of brain CD103-negative CD8+ T cells, and granzyme K-PAR-1 neurotoxicity in cells None not stated not established — pubmed abstract reports no numeric effect size. Nature Communications 2025
✓ Peer-reviewed PMID 40993111
Microglia / neuroinflammation target (preclinical) Medicines Treatment Benefit
why

Direction is for inhibiting C1q, C3 or the microglial receptor CR3, which reduced phagocytic microglia and early synapse loss; C1q was necessary for soluble amyloid-beta oligomers to damage synapses. Mouse work with no human outcome.

Early synapse loss in Alzheimer mouse models None not stated not established — pubmed abstract reports no numeric effect size. Science 2016
✓ Peer-reviewed PMID 27033548
Microglia / neuroinflammation target (preclinical) Medicines Treatment Benefit
why

Direction is for NLRP3 or caspase-1 deficiency, which largely protected the mice from spatial memory loss and reduced amyloid deposition; the human data are limited to raised active caspase-1 in post-mortem MCI and Alzheimer brains.

Spatial memory loss and amyloid deposition in APP/PS1 mice None not stated not established — pubmed abstract reports no numeric effect size. Nature 2013
✓ Peer-reviewed PMID 23254930

How this table was built, and where it is weak →

Last updated